Warfarin-induced skin necrosis in HIV-1-infected patients with tuberculosis and venous thrombosis
At the turn of the century, only 300 cases of warfarin-induced skin necrosis (WISN) had been reported. WISN is a rare but potentially fatal complication of warfarin therapy. There are no published reports of WISN occurring in patients with HIV-1 infection or tuberculosis (TB). We retrospectively rev...
Saved in:
Published in | South African medical journal Vol. 100; no. 6; pp. 372 - 377 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Rondebosch
Health and Medical Publishing Group
01.06.2010
Health & Medical Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | At the turn of the century, only 300 cases of warfarin-induced skin necrosis (WISN) had been reported. WISN is a rare but potentially fatal complication of warfarin therapy. There are no published reports of WISN occurring in patients with HIV-1 infection or tuberculosis (TB).
We retrospectively reviewed cases of WISN presenting from April 2005 to July 2008 at a referral hospital in Cape Town, South Africa.
Six cases of WISN occurred in 973 patients receiving warfarin therapy for venous thrombosis (0.62%, 95% CI 0.25 - 1.37%). All 6 cases occurred in HIV-1-infected women (median age 30 years, range 27 - 42) with microbiologically confirmed TB and venous thrombosis. All were profoundly immunosuppressed (median CD4+ count at TB diagnosis 49 cells/microl, interquartile range 23 - 170). Of the 3 patients receiving combination antiretroviral therapy, 2 had TB-IRIS (immune reconstitution inflammatory syndrome). The median interval from initiation of antituberculosis treatment to venous thrombosis was 37 days (range 0 - 150). The median duration of parallel heparin and warfarin therapy was 2 days (range 1 - 6). WISN manifested 6 days (range 4 - 8) after initiation of warfarin therapy. The international normalised ratio (INR) at WISN onset was supra-therapeutic, median 6.2 (range 3.8 - 6.6). Sites of WISN included breasts, buttocks and thighs. Four of 6 WISN sites were secondarily infected with drug-resistant nosocomial bacteria (methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter, extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae) 17 - 37 days after WISN onset. In 4 patients, the median interval from WISN onset to death was 43 days (range 25 - 45). One of the 2 patients who survived underwent bilateral mastectomies and extensive skin grafting at a specialist centre.
This is one of the largest case series of WISN. We report a novel clinical entity: WISN in HIV-1 infected patients with TB and venous thrombosis. The occurrence of 6 WISN cases in a 40-month period may be attributed to (i) hypercoagulability, secondary to HIV-1 and TB: (ii) short concurrent heparin and warfarin therapy; and (iii) high loading doses of warfarin. Active prevention and appropriate management of WISN are likely to improve the dire morbidity and mortality of this unusual condition. |
---|---|
AbstractList | Background. At the turn of the century, only 300 cases of warfarin-induced skin necrosis (WISN) had been reported. WISN is a rare but potentially fatal complication of warfarin therapy. There are no published reports of WISN occurring in patients with HIV-1 infection or tuberculosis (TB). Methods. We retrospectively reviewed cases of WISN presenting from April 2005 to July 2008 at a referral hospital in Cape Town, South Africa. Results. Six cases of WISN occurred in 973 patients receiving warfarin therapy for venous thrombosis (0.62%, 95% CI 0.25 - 1.37%). All 6 cases occurred in HIV-1-infected women (median age 30 years, range 27 - 42) with microbiologically confirmed TB and venous thrombosis. All were profoundly immunosuppressed (median CD4+ count at TB diagnosis 49 cells/ mu l, interquartile range 23 - 170). Of the 3 patients receiving combination antiretroviral therapy, 2 had TB-IRIS (immune reconstitution inflammatory syndrome). The median interval from initiation of antituberculosis treatment to venous thrombosis was 37 days (range 0 - 150). The median duration of parallel heparin and warfarin therapy was 2 days (range 1 - 6). WISN manifested 6 days (range 4 - 8) after initiation of warfarin therapy. The international normalised ratio (INR) at WISN onset was supra-therapeutic, median 5.6 (range 3.8 - 6.6). Sites of WISN included breasts, buttocks and thighs. Four of 6 WISN sites were secondarily infected with drug-resistant nosocomial bacteria (methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter, extended-spectrum beta -lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae) 17 - 37 days after WISN onset. In 4 patients, the median interval from WISN onset to death was 43 days (range 25 - 45). One of the 2 patients who survived underwent bilateral mastectomies and extensive skin grafting at a specialist centre. Conclusion. This is one of the largest case series of WISN. We report a novel clinical entity: WISN in HIV-1 infected patients with TB and venous thrombosis. The occurrence of 6 WISN cases in a 40-month period may be attributed to (i) hypercoagulability, secondary to HIV-1 and TB; (ii) short concurrent heparin and warfarin therapy; and (iii) high loading doses of warfarin. Active prevention and appropriate management of WISN are likely to improve the dire morbidity and mortality of this unusual condition. Background. At the turn of the century, only 300 cases of warfarin-induced skin necrosis (WISN) had been reported. WISN is a rare but potentially fatal complication of warfarin therapy. There are no published reports of WISN occurring in patients with HIV-1 infection or tuberculosis (TB). Methods. We retrospectively reviewed cases of WISN presenting from April 2005 to July 2008 at a referral hospital in Cape Town, South Africa. Results. Six cases of WISN occurred in 973 patients receiving warfarin therapy for venous thrombosis (0.62%, 95% CI 0.25-1.37%). All 6 cases occurred in HIV-1-infected women (median age 30 years, range 27-42) with microbiologically confirmed TB and venous thrombosis. All were profoundly immunosuppressed (median CD4+ count at TB diagnosis 49 cells/uL interquartile range 23-170). Of the 3 patients receiving combination antiretroviral therapy, 2 had TB-IRIS (immune reconstitution inflammatory syndrome). The median interval from initiation of antituberculosis treatment to venous thrombosis was 37 days (range 0-150). The median duration of parallel heparin and warfarin therapy was 2 days (range 1-6). WISN manifested 6 days (range 4-8) after initiation of warfarin therapy. The international normalised ratio (INR) at WISN onset was supra-therapeutic, median 5.6 (range 3.8-6.6). Sites of WISN included breasts, buttocks and thighs. Four of 6 WISN sites were secondarily infected with drug-resistant nosocomial bacteria (methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter, extended-spectrum P-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae) 17-37 days after WISN onset. In 4 patients, the median interval from WISN onset to death was 43 days (range 25-45). One of the 2 patients who survived underwent bilateral mastectomies and extensive skin grafting at a specialist centre. Conclusion. This is one of the largest case series of WISN. We report a novel clinical entity: WISN in HIV-1 infected patients with TB and venous thrombosis. The occurrence of 6 WISN cases in a 40-month period may be attributed to (i) hypercoagulability, secondary to HIV-1 and TB; (ii) short concurrent heparin and warfarin therapy; and (iii) high loading doses of warfarin. Active prevention and appropriate management of WISN are likely to improve the dire morbidity and mortality of this unusual condition. At the turn of the century, only 300 cases of warfarin-induced skin necrosis (WISN) had been reported. WISN is a rare but potentially fatal complication of warfarin therapy. There are no published reports of WISN occurring in patients with HIV-1 infection or tuberculosis (TB). We retrospectively reviewed cases of WISN presenting from April 2005 to July 2008 at a referral hospital in Cape Town, South Africa. Six cases of WISN occurred in 973 patients receiving warfarin therapy for venous thrombosis (0.62%, 95% CI 0.25 - 1.37%). All 6 cases occurred in HIV-1-infected women (median age 30 years, range 27 - 42) with microbiologically confirmed TB and venous thrombosis. All were profoundly immunosuppressed (median CD4+ count at TB diagnosis 49 cells/microl, interquartile range 23 - 170). Of the 3 patients receiving combination antiretroviral therapy, 2 had TB-IRIS (immune reconstitution inflammatory syndrome). The median interval from initiation of antituberculosis treatment to venous thrombosis was 37 days (range 0 - 150). The median duration of parallel heparin and warfarin therapy was 2 days (range 1 - 6). WISN manifested 6 days (range 4 - 8) after initiation of warfarin therapy. The international normalised ratio (INR) at WISN onset was supra-therapeutic, median 6.2 (range 3.8 - 6.6). Sites of WISN included breasts, buttocks and thighs. Four of 6 WISN sites were secondarily infected with drug-resistant nosocomial bacteria (methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter, extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae) 17 - 37 days after WISN onset. In 4 patients, the median interval from WISN onset to death was 43 days (range 25 - 45). One of the 2 patients who survived underwent bilateral mastectomies and extensive skin grafting at a specialist centre. This is one of the largest case series of WISN. We report a novel clinical entity: WISN in HIV-1 infected patients with TB and venous thrombosis. The occurrence of 6 WISN cases in a 40-month period may be attributed to (i) hypercoagulability, secondary to HIV-1 and TB: (ii) short concurrent heparin and warfarin therapy; and (iii) high loading doses of warfarin. Active prevention and appropriate management of WISN are likely to improve the dire morbidity and mortality of this unusual condition. |
Audience | Academic |
Author | TODD, G BHAIJEE, F DE VRIES, E WAINWRIGHT, H MEINTJES, G WILKINSON, R. J PEPPER, D. J |
Author_xml | – sequence: 1 givenname: F surname: BHAIJEE fullname: BHAIJEE, F organization: Institute of Infectious Diseases and Molecular Medicine and Department of Medicine, University of Cape Town, South Africa – sequence: 2 givenname: H surname: WAINWRIGHT fullname: WAINWRIGHT, H organization: Department of Pathology, Division of Anatomical Pathology, University of Cape Town, South Africa – sequence: 3 givenname: G surname: MEINTJES fullname: MEINTJES, G organization: Institute of Infectious Diseases and Molecular Medicine and Department of Medicine, University of Cape Town; and Infectious Diseases Unit, G F Jooste Hospital, Cape Town, South Africa – sequence: 4 givenname: R. J surname: WILKINSON fullname: WILKINSON, R. J organization: Institute of Infectious Diseases and Molecular Medicine and Department of Medicine, University of Cape Town, South Africa – sequence: 5 givenname: G surname: TODD fullname: TODD, G organization: Department of Dermatology, Groote Schuur Hospital and University of Cape Town, South Africa – sequence: 6 givenname: E surname: DE VRIES fullname: DE VRIES, E organization: School of Public Health and Family Medicine, University of Cape Town, South Africa – sequence: 7 givenname: D. J surname: PEPPER fullname: PEPPER, D. J organization: Institute of Infectious Diseases and Molecular Medicine and Department of Medicine, University of Cape Town; and Infectious Diseases Unit, G F Jooste Hospital, Cape Town, South Africa |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23146723$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20529438$$D View this record in MEDLINE/PubMed |
BookMark | eNptkU1v1DAQhi1URLeFA38ARULAKYs_Yie5VFpVQIuKOPB1jCbOuDEk9mI7Rfx7vHSBroR8GM-8z7zyeE7IkfMOCXnM6LpmrXr5YfPu7VpIJe-RFad1U0om5BFZUS5V2cq6OiYnMX6lOZetekCOOZW8rUSzIvAFgoFgXWndsGgcivjNusKhDj7aWOT7xeXnkmXZoE5Z30Ky6FIsftg0FmnpMehl-g2DG4obdH6JRRqDn_td9SG5b2CK-GgfT8mn168-nl-UV-_fXJ5vrkotRZNK5E1PtaQIZqBUqAbqpjcgTGNEWzGGAhQaDnpgLdZ0EEruouZsaLigRpySs1vf7dLPOOj8xgBTtw12hvCz82C7Q8XZsbv2N52QVHFWZ4MXe4Pgvy8YUzfbqHGawGEeqWtpzZSgNc3k01vyGibs8s_4bKh3dLfhvKmErPiOWv-HymfA2eq8QWNz_aDh-Z2GEWFKY_TTkqx38RB8cnfUvzP-WWsGnu0BiBomE8BpG_9xglWq5kL8Av2vsgU |
CODEN | SAMJAF |
CitedBy_id | crossref_primary_10_7861_clinmedicine_12_1_90 crossref_primary_10_1007_s11239_012_0748_0 |
ContentType | Journal Article |
Copyright | 2015 INIST-CNRS COPYRIGHT 2010 Health & Medical Publishing Group |
Copyright_xml | – notice: 2015 INIST-CNRS – notice: COPYRIGHT 2010 Health & Medical Publishing Group |
DBID | IQODW CGR CUY CVF ECM EIF NPM 7QL C1K 5PM |
DOI | 10.7196/SAMJ.3565 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management |
DatabaseTitleList | Bacteriology Abstracts (Microbiology B) MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2078-5135 |
EndPage | 377 |
ExternalDocumentID | A228435420 20529438 23146723 |
Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GeographicLocations | South Africa |
GeographicLocations_xml | – name: South Africa |
GrantInformation_xml | – fundername: Wellcome Trust – fundername: Wellcome Trust grantid: 084323 – fundername: Medical Research Council grantid: MC_U117588499 – fundername: Wellcome Trust grantid: 088316 – fundername: Wellcome Trust grantid: 072070 – fundername: FIC NIH HHS grantid: U2R TW007373 – fundername: PHS HHS grantid: 1U2RTW007373-01A1 – fundername: Medical Research Council grantid: U117588499(88499) – fundername: Wellcome Trust : grantid: 084323 || WT – fundername: Wellcome Trust : grantid: 088316 || WT – fundername: Wellcome Trust : grantid: 072070 || WT – fundername: Medical Research Council : grantid: U117588499(88499) || MRC_ |
GroupedDBID | --- -OY .55 .GJ 123 1RG 4JU 53G 5RE 5VS 6SC AAFWJ AAUGY AAWTL ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS APOWU AZFZN BAWUL BCNDV DIK EBD EBS EJD EMOBN F5P FRP GROUPED_DOAJ GX1 IAO IHR IHW INH INR IPNFZ IQODW ITC J5H JRA KWQ L7B MK0 OK1 P2P RFP RIG RNS SV3 SWNBY TR2 W2D X7M ZGI ZXP CGR CUY CVF ECM EIF NPM SCVUT 7QL C1K 5PM |
ID | FETCH-LOGICAL-c538t-e28b0c50eafd00368a78bfa3f8f39411e3a6ef2acd19e70d3659e70c21d8230f3 |
ISSN | 0256-9574 |
IngestDate | Tue Sep 17 21:19:25 EDT 2024 Fri Jun 28 07:16:08 EDT 2024 Wed Jul 24 18:24:15 EDT 2024 Tue Jul 23 04:35:01 EDT 2024 Tue Jul 23 02:32:30 EDT 2024 Thu May 23 23:39:01 EDT 2024 Sun Oct 22 16:07:57 EDT 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | Immunopathology Warfarin Cardiovascular disease AIDS Anticoagulant Mycobacterial infection Immune deficiency Venous disease Necrosis Infection Vascular disease Tuberculosis Viral disease Bacteriosis Tropical medicine Skin Venous thrombosis |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c538t-e28b0c50eafd00368a78bfa3f8f39411e3a6ef2acd19e70d3659e70c21d8230f3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S0256-95742010000600018&lng=en&tlng=en |
PMID | 20529438 |
PQID | 907163070 |
PQPubID | 23462 |
PageCount | 6 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3506217 proquest_miscellaneous_907163070 gale_infotracmisc_A228435420 gale_infotracacademiconefile_A228435420 gale_healthsolutions_A228435420 pubmed_primary_20529438 pascalfrancis_primary_23146723 |
PublicationCentury | 2000 |
PublicationDate | 2010-06-01 |
PublicationDateYYYYMMDD | 2010-06-01 |
PublicationDate_xml | – month: 06 year: 2010 text: 2010-06-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Rondebosch |
PublicationPlace_xml | – name: Rondebosch – name: South Africa |
PublicationTitle | South African medical journal |
PublicationTitleAlternate | S Afr Med J |
PublicationYear | 2010 |
Publisher | Health and Medical Publishing Group Health & Medical Publishing Group |
Publisher_xml | – name: Health and Medical Publishing Group – name: Health & Medical Publishing Group |
SSID | ssj0025596 ssib045324610 ssib022775494 ssib005229541 |
Score | 1.9162303 |
Snippet | At the turn of the century, only 300 cases of warfarin-induced skin necrosis (WISN) had been reported. WISN is a rare but potentially fatal complication of... Background. At the turn of the century, only 300 cases of warfarin-induced skin necrosis (WISN) had been reported. WISN is a rare but potentially fatal... |
SourceID | pubmedcentral proquest gale pubmed pascalfrancis |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 372 |
SubjectTerms | Acinetobacter Adult Anticoagulants - adverse effects Bacterial diseases Biological and medical sciences Care and treatment Comorbidity Complications and side effects Dosage and administration Escherichia coli Female General aspects HIV Infections - epidemiology HIV patients Human bacterial diseases Human immunodeficiency virus 1 Human viral diseases Humans Infectious diseases Klebsiella pneumoniae Medical sciences Mycobacterium Necrosis Necrosis - chemically induced Retrospective Studies Risk factors Skin - drug effects Skin - pathology Staphylococcus aureus Tuberculosis Tuberculosis - epidemiology Tuberculosis and atypical mycobacterial infections Tuberculosis, Pulmonary - epidemiology Venous thrombosis Venous Thrombosis - epidemiology Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Warfarin Warfarin - adverse effects |
Title | Warfarin-induced skin necrosis in HIV-1-infected patients with tuberculosis and venous thrombosis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/20529438 https://search.proquest.com/docview/907163070 https://pubmed.ncbi.nlm.nih.gov/PMC3506217 |
Volume | 100 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaWIiEkhHiWQFl8QOJQpSRxnscVAi2VlgNq6Z6IbMdR01Kz2mZB4tczEzveZFUk4JJEfiXyfLFnPC9CXucFzyuRSj-XIvDjhEm_EKnywzznos4w4gn6Di8-pfPT-HiZLCeTrwOrpU0rjuSvG_1K_oeqUAZ0RS_Zf6CsGxQK4BnoC1egMFz_isZnfF2DrKt9EKw3qMi_vmz0oVa49TWdoev84xeQ3ozFFdTbKKrWpa3dCLWWm29dYzxA_2ECtmLqhCuBpUPWtUu2d2jyCmmjk99GnnBS_TlvLtTYZPiMN_qnOwRwqqmFanR7ofqc7e7459L5o322Oit7KIH69N54yq5dwEn5RWIS8LiFNggGiBoum8yk79ldzjNYHlChPFscH7HE5JQYkHV11dE1QmVlbGLE7MTO7qtukdtRBp-DzuBLZwKE0lSny-4_1kSewre-de_EaNF2FLdr31vxa5ji2qQ-uUk22TWxHfAsJw_IfSts0JlBzkMyUfoRubOw5hSPCd8FEEUA0R5AFJ7HAKI9gCgCiA4BRAFA1ACIbgH0hJx-eH_ybu7bnBu-hK2v9VWUi0AmgeJ1hbGKcp7louaszmtWxGGoGE9VHXFZhYXKgoqlCd5lFFaosq3ZU7Knv2v1jNCqYsD6RCoRFSZFq_KEJ1UWxLIIUh5nsUde4XSWxuHX_Y_lLAKWiUGXwCNvuhZIb5hFya3LCIyPUctGLQ9GLWGNlKPq6Yhk5cqEcilBugFOIWIeoT0NS-yLlodawYyVBfDgKW6MHtk3JN12trjwSDYitmuAodvHNbo570K4syRIozB7_scxX5C72__qgOy16416CexvK6bdsdG0Q_Jv_8uzHQ |
link.rule.ids | 230,315,786,790,870,891,27957,27958 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Warfarin-induced+skin+necrosis+in+HIV-1-infected+patients+with+tuberculosis+and+venous+thrombosis&rft.jtitle=South+African+medical+journal&rft.au=Bhaijee%2C+F&rft.au=Wainwright%2C+H&rft.au=Meintjes%2C+G&rft.au=Wilkinson%2C+R+J&rft.date=2010-06-01&rft.issn=0256-9574&rft.volume=100&rft.issue=6&rft.spage=372&rft_id=info:doi/10.7196%2FSAMJ.3565&rft_id=info%3Apmid%2F20529438&rft.externalDocID=20529438 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0256-9574&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0256-9574&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0256-9574&client=summon |